# Capecitabine For Nasopharyngeal Cancer

> **NCT00095901** · PHASE2 · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 3 (actual)

## Conditions studied

- Head and Neck Cancer

## Interventions

- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT00095901
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-06
- **Primary completion:** 2007-05
- **Final completion:** 2007-05
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2018-03-29

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00095901

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00095901, "Capecitabine For Nasopharyngeal Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00095901. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*